On Wednesday, Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), subtract -6.16% and closed at $12.80 in the last trading session. The last trading range of the stock ranges between $12.79 and $13.72. The company’s Market capitalization is $2.37 Billion with the total Outstanding Shares of 192.71 million. During the 52-week trading session the minimum price at which share price traded, registered at $4.37 and reached to max level of $14.34. ARIAD Pharmaceuticals, Inc. (ARIA) recently declared updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
The updated Phase 1/2 results were included in a poster presentation on Sunday, October 9 at the 41st Annual Congress of the European Society for Medical Oncology (ESMO) held in Copenhagen, Denmark.
Phase 1/2 Study
The data presented at ESMO include safety analyses on all patients in the trial (N=137) and efficacy analyses on all patients with ALK+ NSCLC (n=79). Of the 79 ALK+ NSCLC patients, all but eight had failed prior crizotinib therapy. The presentation is based on patient data as of May 2016 with a median time on brigatinib treatment for ALK+ NSCLC patients of 20.0 months (range, 0.03 – 47.4 months, ongoing). Patient enrollment in the trial is complete, with the last patient enrolled in July 2014.
Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), dropped -0.97% and closed at $44.12 in the last trading session. The last trading range of the stock ranges between $44.00 and $44.76. The company’s Market capitalization is $45.29 Billion with the total Outstanding Shares of 1.01 billion. During the 52-week trading session the minimum price at which share price traded, registered at $44.00 and reached to max level of $66.55. Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) recently declared the launch of RAJANITM (drospirenone, ethinyl estradiol and levomefolate calcium tablets, 3 mg/0.02 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg) in the United States. RAJANITM, the generic equivalent of Beyaz®1, is an oral contraceptive, available in a 28-day blister pack dispenser, for use by women to:
- treat symptoms of premenstrual dysphoric disorder (PMDD) in women choosing to use an oral contraceptive for contraception;
- treat moderate acne for women at least 14 years old if the patient desires an oral contraceptive for birth control; and
- raise folate levels in women who choose to use an oral contraceptive for contraception.
Teva is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the leading portfolio of FDA-approved generic products on the market. This product enhances Teva’s already comprehensive oral contraceptive portfolio.
Lam Research Corporation (NASDAQ:LRCX), lost -0.91% and closed at $96.68 in the last trading session. The last trading range of the stock ranges between $96.81 and $99.09. During the 52-week trading session the minimum price at which share price traded, registered at $63.10 and reached to max level of $102.44. Lam Research Corp. (LRCX) and KLA-Tencor (KLAC) recently declared that they have mutually agreed to terminate their projected merger agreement. After careful review of recent antitrust agency feedback and evaluation of their options, both companies have decided that it is not in the best interest of their respective stakeholders to continue pursuing the merger. In accordance with terms set forth in the merger agreement, no termination fees will be payable by either company.
“We believe that this projected combination would have resulted in compelling benefits for our customers, employees and stockholders, in addition to accelerate innovation in the broader semiconductor industry, so we are disdesignated with the outcome. However, together with our customers, we have affirmed the value of closer cooperation between process and process control for new enabling solutions, for that reason, we plan to explore partnershipopportunities with KLA-Tencor around programs identified as beneficial to our customers,” said Martin Anstice, president and chief executive officer.